Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
[Optical coherence tomography in multiple sclerosis].
MRI in multiple sclerosis: a review of the current literature.
Santhera Receives European Marketing Authorization for Raxone® in Leber's Hereditary Optic Neuropathy (LHON)
Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease.
Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
Potential T cell epitopes of Mycobacterium tuberculosis that can instigate molecular mimicry against host: implications in autoimmune pathogenesis.
Energy Cost of Walking and Its Association With Gait Parameters, Daily Activity, and Fatigue in Persons With Mild Multiple Sclerosis.
The influence of HLA-DRB1*15 on motor cortical pathology in multiple sclerosis.
Lodonal/LDN
Early activation of CD4+ and CD8+ T lymphocytes by myelin basic protein in subjects with MS.
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis
Acute disseminated encephalomyelitis--a prospective study of clinical profile and in-hospital outcome predictors.
Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
Oral dalfampridine improves standing balance detected at static posturography in multiple sclerosis.
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Ampyra (dalfampridine) medication guide
A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01.
Evaluation of sexual function in women at two stages of multiple sclerosis.
Bullous pemphigoid in a patient with multiple sclerosis being treated with human immunoglobulin.
In vitro Biological Characterization of IFN-β-1a major Glycoforms.
Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden.
Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
The ketogenic diet as a treatment paradigm for diverse neurological disorders.
Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis.
Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis.
Pages
« first
‹ previous
…
155
156
157
158
159
160
161
162
163
…
next ›
last »